A Survey of Lanadelumab in Participants With Hereditary Angioedema

Takeda

Status: Completed

Conditions: Hereditary Angioedema (HAE)

Treatments: Drug: Lanadelumab

Study type: Observational

Funder types: Industry

Identifiers

NCT05397431

TAK-743-4004

jRCT2031220105 (Registry Identifier)

Details and patient eligibility

About

This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Lanadelumab and to check if Lanadelumab improves symptoms of HAE. During the study, participants with HAE will take Lanadelumab subcutaneous injection according to their clinic's standard practice. The study doctors will check for side effects from Lanadelumab for 12 months.

Enrollment: 155 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria - Participants diagnosed with hereditary angioedema (HAE) and treated with Lanadelumab for the first time.

Exclusion Criteria

- None

Trial design

155 participants in 1 patient group

Lanadelumab

Description:

Participants will receive 300 milligram (mg) of Lanadelumab Subcutaneous (SC) injection once every 2 weeks.

Treatment:

Drug: Lanadelumab